Basic Information
| LncRNA/CircRNA Name | circCCDC66 |
| Synonyms | |
| Region | |
| Ensemble | |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, luciferin reporter assays, biotin-coupled RNA pull-downs and fluorescence |
| Sample | gastric cancer tissues and cell lines |
| Expression Pattern | up-regulated |
| Function Description | CircCCDC66 was overexpressed in CDDP-resistant cells and tissues. The circCCDC66 expression was significantly associated with malignancy and was an independent risk factor for disease-free survival (DFS) in GC patients treated by CDDP based chemotherapy. |
| Pubmed ID | 32253030 |
| Year | 2020 |
| Title | CircRNACCDC66 regulates cisplatin resistance in gastric cancer via the miR-618/BCL2 axis |
External Links
| Links for circCCDC66 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |